Journal
MABS
Volume 13, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2021.1914883
Keywords
EGFR; HER2; HER3; pancreatic cancer; gemcitabine; Pan-Her; chemoresistance
Categories
Funding
- Programme Investissement d'Avenir [ANR-10-LABX-53-01]
- ANR DUAL PancHER
- Agence Nationale de la Recherche [ANR-16-CE17-002]
Ask authors/readers for more resources
Chemoresistance, particularly to gemcitabine, presents a significant challenge in pancreatic cancer, and the expression of EGFR, HER2, and HER3 is associated with tumor aggressiveness and therapeutic resistance. Antibody cocktails targeting these three receptors have shown promise in overcoming resistance in both gemcitabine-sensitive and -resistant pancreatic cancer models.
Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant therapeutic targets due to their synergistic interaction to promote tumor aggressiveness and therapeutic resistance. Cocktails of antibodies directed against different targets are a promising strategy to overcome these processes. Here, we found by immunohistochemistry that these three receptors were co-expressed in 11% of patients with pancreatic adenocarcinoma. We then developed gemcitabine-resistant pancreatic cancer cell models (SW-1990-GR and BxPC3-GR) and one patient-derived xenograft (PDX2846-GR) by successive exposure to increasing doses of gemcitabine. We showed that expression of EGFR, HER2 and HER3 was increased in these gemcitabine-resistant pancreatic cancer models, and that an antibody mixture against all three receptors inhibited tumor growth in mice and downregulated HER receptors. Finally, we demonstrated that the Pan-HER and gemcitabine combination has an additive effect in vitro and in mice xenografted with the gemcitabine-sensitive or resistant pancreatic models. The mixture of anti-EGFR, HER2 and HER3 antibodies is a good candidate therapeutic approach for gemcitabine-sensitive and -resistant pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available